Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
US9198912B2 · kind B2 · utility
Assignees
Inventor
Key dates
| Filing date | Nov 19, 2010 |
| Grant date | Dec 1, 2015 |
| Priority date | — |
| Expiry date | Nov 19, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NARTI) selected from lamivudine and emtricitabine; a nucleoside or nucleotide reverse transcriptase inhibitor (NARTI) selected from didanosine, abacavir and tenofovir; and the combination of ritonavir with a protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir; or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine; for daily administration to said human being one to four days per week.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.